Efficacy and tolerability of once‐monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once‐monthly oral ibandronate has been developed to overcome this problem. OBJECTIVE: To confirm the 1 year results and provide more e...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Reginster, J‐Y, Adami, S, Lakatos, P, Greenwald, M, Stepan, J J, Silverman, S L, Christiansen, C, Rowell, L, Mairon, N, Bonvoisin, B, Drezner, M K, Emkey, R, Felsenberg, D, Cooper, C, Delmas, P D, Miller, P D
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Group 2006
Assuntos:
Extended Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798147/
https://ncbi.nlm.nih.gov/pubmed/16339289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044958
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares